ANI and Amneal Set for Q4 Earnings as Specialty Pharma Momentum Builds

ANI Pharmaceuticals (ANIP) is entering its Q4 2025 earnings announcement with a formidable track record, having beaten earnings per share (EPS) estimates in 100% of its quarterly reports over the last two years. The consensus EPS estimate of $1.15 represents a 15% year-over-year increase, while revenue is projected to surge by 28.2% to $168.4 million. This growth is largely attributed to the company’s strategic pivot toward rare diseases and high-margin specialty products, most notably the continued market penetration of Purified Cortrophin Gel. As ANI transitions from a traditional generics player to a diversified specialty pharmaceutical firm, investors will be closely monitoring its ability to maintain these margins amidst a shifting regulatory landscape for orphan drugs.

Amneal Pharmaceuticals (AMRX) presents a different profile, operating at a significantly larger scale with projected Q4 revenue of $686.2 million, an 11.2% increase over the prior year. However, its EPS estimate of $0.14 suggests flat growth, reflecting the intense pricing pressures inherent in the broader generics market. Amneal’s strategy has increasingly focused on complex generics and biosimilars, which offer higher barriers to entry and more sustainable pricing than standard small-molecule generics. The upcoming earnings call will likely highlight the performance of its biosimilar portfolio, including its versions of Neupogen and Neulasta, as well as its progress in the Parkinson’s disease treatment space with IPX203. The company has maintained a 75% revenue beat rate over the last eight quarters, suggesting a stable operational execution despite the thin margins.

“

The consensus EPS estimate of $1.15 represents a 15% year-over-year increase, while revenue is projected to surge by 28.2% to $168.4 million.

In the diagnostics sector, Fulgent Genetics (FLGT) continues its post-pandemic evolution. With a consensus revenue estimate of $71.1 million—a modest 1.1% year-over-year increase—and a projected EPS loss of $0.34, the company is clearly in a reinvestment phase. Fulgent has been aggressively pivoting toward oncology and reproductive health testing to offset the decline in COVID-19 testing revenue. Analysts will be looking for signs that its core genetic testing business is gaining enough traction to achieve profitability in the near term. The company’s 88% beat rate for both EPS and revenue over the last two years suggests that management has been conservative in its guidance, potentially setting the stage for another positive surprise if clinical testing volumes exceed expectations.